U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07131813) titled 'Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus' on Aug. 13.
Brief Summary: Many of the patients with oral lichen planus (OLP) either fail to achieve complete remission or experience frequent relapses with conventional topical corticosteroid therapy, which is currently the mainstay of treatment. Long-term corticosteroid use is limited by local and systemic adverse effects, and many patients develop steroid resistance or intolerance. To overcome these limitations, combination therapy with agents having complementary mechanisms may improve therapeutic outcomes, reduce steroid requirements, a...